![]() |
| Radius Selects First Preclinical Candidate From SARM Discov |
|
RSS FEED
|
Radius Health ("Radius") announced that the company has selected the first lead candidate, RAD140, from its internal nonsteroidal selective androgen receptor modulator ("SARM") discovery program, for full preclinical development as a potential therapy for the treatment of age-related muscle loss (sarcopenia) and other musculoskeletal conditions such as osteoporosis.
Read more... |
||||||||||||
|
|
|||||||||||||
| Radius Selects First Preclinical Candidate From SARM Discov |
|
||
|
Site Map
|
Sitemap |
